Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00393965
Status:
COMPLETED
Last Update Posted:
2008-02-13
First Post:
2006-10-30
Brief Title:
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Sponsor:
Myrexis Inc
Organization:
Myrexis Inc
Study Overview
Official Title:
Phase 1 Open Label Dose Escalating Multiple Dose Study to Determine the Safety Tolerability Maximum Tolerated Dose and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3 Repeated Every 28 Days in Subjects With Refractory Brain Metastases
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 1 Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None